POZ - Latino Hub : Treatment News : HIV Drug Abacavir Increased Heart Attack Risk by 95 Percent in Danish Study

POZ Latino / Hispanic Hub
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
 

Back to home » News & Views » Treatment News


 

March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007


emailrssprint

February 4, 2010

HIV Drug Abacavir Increased Heart Attack Risk by 95 Percent in Danish Study

A study conducted in Denmark suggests abacavir (found in Ziagen, Epzicom and Trizivir) increases the risk of a heart attack by 95 percent—a risk that remains elevated even after the drug is stopped—according to a study published in the February edition of HIV Medicine and reported by aidsmap.

Abacavir was first found to be associated with an increased risk of heart attacks in the 33,000-patient Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. According to a report at the Conference on Retroviruses and Opportunistic Infections in February 2008 in Boston, abacavir increased the relative risk of a heart attack by 90 percent, despite the fact that the drug had never been known to contribute in any way to cardiovascular disease (CVD). More recently, the relative risk of a heart attack associated abacavir downgraded to 70 percent, now that more data regarding confounding factors—notably cholesterol and triglyceride levels—are available.

The D:A:D findings were echoed later that year in data from the Strategies for the Management of Antiretroviral Therapy (SMART) study, first reported at the XVII International AIDS Conference (IAC) in Mexico City. According to SMART, patients using abacavir were 4.3 times more likely to have a heart attack than those not using the drug. And an analysis of 54 clinical trials conducted by abacavir’s manufacturer, ViiV Healthcare (then GlaxoSmithKline) concluded that heart attack and stroke rates were no higher among those using the med, which is classified as a nucleoside reserve transcriptase inhibitor.

Data indicating a neutral effect of abacavir on heart attack risk have also been reported. A study by the federally funded AIDS Clinical Trials Group (ACTG study A5001) evaluated more than 3,200 patients starting their first ARV regimen. It discovered a 2 percent increase in the risk of a heart attack among recent abacavir users—but this finding was not statistically significant.

The latest study, reported by Niels Obel, MD, of Copenhagen University Hospital and his colleagues, evaluated the impact of abacavir therapy and the risk of hospitalization because of heart attacks among 2,930 HIV-positive patients in Denmark. Not only did the study authors look for the incidence of heart attacks among the volunteers, but they also looked for the same confounding variables—such as age, gender, elevated blood lipid levels, high blood pressure and the presence of other diseases known to be associated with CVD risk—that were included in more recent studies.

Of the 2,930 individuals in the cohort, aidsmap reports, 1,761 were treated with abacavir. A little over a third of these patients started HIV treatment with a regimen that included abacavir, and the remaining 66 percent of individuals switched to the drug at least two years after initiating antiretroviral therapy. A total of 67 heart attacks were observed. Of these, 36 occurred after treatment with abacavir was started.

Among those currently using the drug, the relative risk of a heart attack was 95 percent. Interestingly—and in contrast with the findings of D:A:D—the relative risk of a heart attacked remained high, around 137 percent, even after the drug was discontinued.

As the Danish researchers sum up: “We confirmed the finding of the D:A:D study of an increased risk of [heart attack] after initiation of abacavir therapy.”

NEW! Scroll down to comment on this story.

emailrssprint

 

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 2 (of 2 total)    

Steve, Morristown, NJ, 2010-02-10 19:24:52
Thanks, David! I can't STAND bulletins where facts are "left out," or not mentioned as they SHOULD be. Here are those risk factors mentioned... The cardiovascular risk of abacavir, he and his SMART colleagues found, was only significant among those with five or more other risk factors, including being male, smoking cigarettes and having high blood pressure, increased cholesterol or diabetes. The increased risk was NOT significant in those with fewer than five other cardiovascular risk factors.

David C, Seattle WA, 2010-02-10 12:07:16
Those reading this story should definitly click on the "an analysis" link in the 3rd paragraph. It clearly states that the risk of heart attack is ONLY elevated if the patient has at least 5 other risk factors listed. A very important detail that was somehow left out of this otherwise alarming article.

comments 1 - 2 (of 2 total)    


[Go to top]

Protesters hold the Hershey Company and its affiliated school accountable for condoning HIV-related discrimination. Click here to read more.
What to do if you've just been diagnosed
Qué hacer si eres recién diagnosticado

How to find a support system
Cómo encontrar un sistema de apoyo

Things you should know before starting treatment
Cosas que deberías saber antes de comenzar un tratamiento

How to handle side effects and other concerns
Cómo tratar los efectos secundarios y otros problemas de salud

How to tell someone you have HIV/AIDS
Cómo revelar tu diagnóstico de VIH/SIDA
[an error occurred while processing this directive]
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.